secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2024-12-30T23:59:59+00:00
Accession:  0001847903-24-000192
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 1.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa enters up to $200M loan with Oxford Finance, repays $110M Oberland debt
--------------------------------------------------------------------------------

- Initial $110M term loan funded; proceeds used to repay existing NPA with Oberland Capital in full.
- Additional $40M available upon clinical milestone, $50M at lenders' sole discretion; maturity Dec 2029 or Dec 2030 if milestone met.
- Interest rate floating at SOFR (floor 3.28%) + 5.00% margin; min 8.28%, max 10.50%.
- Loan secured by substantially all assets including IP; minimum cash covenant begins Oct 2026, waived if market cap ≥$1B.
- Termination of prior note purchase agreement with Oberland Capital dated Oct 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790324000192/0001847903-24-000192-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790324000192/cnta-20241230.htm
  HTML page:      https://secwatch.observer/filing/0001847903-24-000192

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer